Delivery Order SPE2DB24D1021-SPE2DB25FFABL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,834.81 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pens on August 5, 2025, with an ultimate completion date of August 6, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order valued at $3,809.26 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pens on July 28, 2025, with completion scheduled for July 29, 2025. This non-competitive delivery order utilizes firm fixed pricing and is performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded a $2,239.89 delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 mL pens on September 2, 2025, with completion scheduled for September 3, 2025. This competitive award utilizes firm fixed pricing and represents a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran...
- The Defense Logistics Agency awarded a $6,383.18 delivery order to AmerisourceBergen Drug Corp for Mounjaro 7.5 mg/0.5 ml pen pharmaceutical supplies, with an ultimate completion date of August 18, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The contract contains no set-aside designation...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a $3,228.25 delivery order on August 29, 2025, for the supply of Mounjaro 7.5 mg/0.5 ml pens with a completion date of September 2, 2025. This is a firm fixed price delivery order with no set-aside designation, meaning the award was competitively issued. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $3,267.81 delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Mounjaro 7.5 mg/0.5 mL pens. The contract is a firm fixed price delivery order with an ultimate completion date of August 29, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This award was competitively procured with no set-aside designation and represents a child contract under AmerisourceBergen's existing Indefinite...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $12,761.93 for Mounjaro 5 mg/0.5 ml pens on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a...
- The Defense Logistics Agency awarded a $15,269.80 firm fixed price delivery order to AmerisourceBergen Drug Corp for Mounjaro 2.5 mg/0.5 mL pens on August 11, 2025, with an ultimate completion date of August 12, 2025. This non-set-aside competitive award represents a single delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The pharmaceutical will be delivered to the company's...
- The Defense Logistics Agency awarded a delivery order valued at $17,489.37 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen injections. This non-set-aside, firm fixed-price delivery order was competitively awarded on August 15, 2025, with an ultimate completion date of August 18, 2025. The product will be delivered to AmerisourceBergen's location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order valued at $2,833.74 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pen (0.5 mL), a diabetes medication. The contract, awarded on September 10, 2025, with an ultimate completion date of September 11, 2025, represents a firm fixed price delivery order with no set-aside designation. Performance will take place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under...
- SPE2DB24D1021Indefinite Delivery Contract
- SPE2DB24D1021-SPE2DB25FFABLDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,486.67 to AmerisourceBergen Drug Corp for the supply of Mounjaro 7.5 mg/0.5 mL pens with a completion date of August 28, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued as a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. Mounjaro is a diabetes medication used for glycemic control, consistent with AmerisourceBergen's extensive federal contract portfolio of pharmaceutical products and medical supplies supporting military and veteran healthcare systems. As a major pharmaceutical distributor and critical vendor in the federal medical procurement ecosystem, AmerisourceBergen supplies a comprehensive range of therapeutics including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains. This delivery order represents one of numerous competitively awarded transactions through which the company fulfills federal medical supply requirements, leveraging its established prime vendor relationship with the DLA to support Defense Health Agency operations and other government healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.5k | 8/27/25 |